Karina Hansen

937 total citations
28 papers, 696 citations indexed

About

Karina Hansen is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Pharmacology. According to data from OpenAlex, Karina Hansen has authored 28 papers receiving a total of 696 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 8 papers in Economics and Econometrics and 5 papers in Pharmacology. Recurrent topics in Karina Hansen's work include Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (8 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Karina Hansen is often cited by papers focused on Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (8 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Karina Hansen collaborates with scholars based in Denmark, France and United States. Karina Hansen's co-authors include Mondher Toumi, Jean‐Michel Azorin, Matthias C. Angermeyer, Christophe Sapin, Steven Marwaha, Paul Bebbington, Traolach Brugha, Sonia Johnson, Reinhold Kilian and Mai Stafford and has published in prestigious journals such as PLoS ONE, The British Journal of Psychiatry and Schizophrenia Research.

In The Last Decade

Karina Hansen

27 papers receiving 663 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karina Hansen Denmark 14 500 186 172 115 114 28 696
Antonio Ciudad Spain 17 668 1.3× 208 1.1× 126 0.7× 128 1.1× 218 1.9× 43 834
Patrick Aquino United States 6 660 1.3× 182 1.0× 103 0.6× 103 0.9× 188 1.6× 13 899
Ola Granström Sweden 8 474 0.9× 190 1.0× 132 0.8× 56 0.5× 84 0.7× 13 722
Hany G El-Sayeh United Kingdom 11 695 1.4× 221 1.2× 84 0.5× 134 1.2× 183 1.6× 22 931
Teresa Díez Spain 12 806 1.6× 324 1.7× 141 0.8× 104 0.9× 126 1.1× 30 1.1k
Myrlene Sanon Aigbogun United States 13 453 0.9× 151 0.8× 108 0.6× 57 0.5× 63 0.6× 23 736
Verity Humberstone New Zealand 10 644 1.3× 264 1.4× 133 0.8× 87 0.8× 193 1.7× 15 827
Joan M. Anzia United States 8 418 0.8× 208 1.1× 112 0.7× 48 0.4× 111 1.0× 16 701
Seung-Hee Hong United States 7 468 0.9× 250 1.3× 89 0.5× 70 0.6× 108 0.9× 10 890
Elmārs Rancāns Latvia 17 254 0.5× 282 1.5× 146 0.8× 72 0.6× 55 0.5× 66 682

Countries citing papers authored by Karina Hansen

Since Specialization
Citations

This map shows the geographic impact of Karina Hansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karina Hansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karina Hansen more than expected).

Fields of papers citing papers by Karina Hansen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karina Hansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karina Hansen. The network helps show where Karina Hansen may publish in the future.

Co-authorship network of co-authors of Karina Hansen

This figure shows the co-authorship network connecting the top 25 collaborators of Karina Hansen. A scholar is included among the top collaborators of Karina Hansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karina Hansen. Karina Hansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hansen, Karina, et al.. (2024). Mental Health Assessment and Psychosocial Intervention Are Already Happening for Maternal-Fetal Interventions. The Journal of Clinical Psychiatry. 85(4).
2.
Colgan, William, et al.. (2024). Ice acceleration and rotation in the Greenland Ice Sheet interior in recent decades. Communications Earth & Environment. 5(1). 1 indexed citations
3.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2017). Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study. PLoS ONE. 12(8). e0183475–e0183475. 6 indexed citations
4.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2017). Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate. International Clinical Psychopharmacology. 32(3). 147–154. 19 indexed citations
5.
Potkin, Steven G., Jean‐Yves Loze, Carlos Forray, et al.. (2016). Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. The International Journal of Neuropsychopharmacology. 20(1). pyw093–pyw093. 21 indexed citations
6.
Naber, Dieter, Karina Hansen, Carlos Forray, et al.. (2015). Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophrenia Research. 168(1-2). 498–504. 118 indexed citations
7.
Citrome, Leslie, Siddhesh Kamat, Christophe Sapin, et al.. (2014). Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. Journal of Medical Economics. 17(8). 567–576. 20 indexed citations
8.
Sawyer, Laura, et al.. (2014). Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. Journal of Medical Economics. 17(7). 508–519. 12 indexed citations
9.
Heider, Dirk, A. Millier, Jean‐Michel Azorin, et al.. (2012). A prospective study of health care resource utilisation and selected costs of schizophrenia in France. BMC Health Services Research. 12(1). 269–76. 16 indexed citations
10.
Lindström, Eva, et al.. (2011). A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nordic Journal of Psychiatry. 65(6). 403–413. 17 indexed citations
11.
Ereshefsky, Larry, Delphine Saragoussi, Nicolas Despiégel, et al.. (2010). The 6-month persistence on SSRIs and associated economic burden. Journal of Medical Economics. 13(3). 527–536. 22 indexed citations
12.
Xie, Feng, Nicolas Despiégel, Natalya Danchenko, & Karina Hansen. (2008). Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice. 13(1). 59–69. 3 indexed citations
13.
Wade, Alan, José‐Luis Fernández, C. François, et al.. (2008). Escitalopram and Duloxetine in Major Depressive Disorder. PharmacoEconomics. 26(11). 969–981. 34 indexed citations
14.
Lançon, Christophe, Mondher Toumi, Christophe Sapin, & Karina Hansen. (2008). The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe. BMC Psychiatry. 8(1). 57–57. 13 indexed citations
15.
Azorin, Jean‐Michel, et al.. (2008). Evaluation of patients on sertindole treatment after failure of other antipsychotics: A retrospective analysis. BMC Psychiatry. 8(1). 16–16. 9 indexed citations
16.
Hansen, Karina, R Launois, & Christophe Sapin. (2007). Pharmacoeconomic Positioning of Sertindole among Atypical Antipsychotics in the Management of Schizophrenia in Turkey. SSRN Electronic Journal. 2 indexed citations
17.
Marwaha, Steven, Sonia Johnson, Paul Bebbington, et al.. (2007). Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. The British Journal of Psychiatry. 191(1). 30–37. 251 indexed citations
18.
Hansen, Karina, István Bitter, R Launois, & Christophe Sapin. (2006). PMH14 PHARMACOECONOMIC POSITIONING OF SERTINDOLE AMONG ANTIPSYCHOTICS IN THE MANAGEMENT OF SCHIZOPHRENIA: THE HUNGARIAN EXPERIENCE. Value in Health. 9(6). A313–A314. 1 indexed citations
19.
Hansen, Karina, Christophe Lançon, & Mondher Toumi. (2005). Pharmacoeconomic modelling in schizophrenia. The European Journal of Health Economics. 7(1). 19–29. 6 indexed citations
20.
Hansen, Karina, C. François, Mondher Toumi, & Christophe Lançon. (2002). A pharmacoeconomic evaluation of zuclopenthixol compared with haloperidol and risperidone in the treatment of schizophrenia. The European Journal of Health Economics. 3(3). 173–179. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antonio Ciudad Breakdown of academic impact, for papers by Patrick Aquino Breakdown of academic impact, for papers by Ola Granström Breakdown of academic impact, for papers by Hany G El-Sayeh Breakdown of academic impact, for papers by Teresa Díez Breakdown of academic impact, for papers by Myrlene Sanon Aigbogun Breakdown of academic impact, for papers by Verity Humberstone Breakdown of academic impact, for papers by Joan M. Anzia Breakdown of academic impact, for papers by Seung-Hee Hong Breakdown of academic impact, for papers by Elmārs Rancāns
Rankless by CCL
2026